FDA hands Y-mAbs refusal to file letter in one of its pediatric neuroblastoma programs

In what had looked like a promising year for Y-mAbs Therapeutics $YMAB as its two main neuroblastoma programs headed to the FDA, the company hit a roadblock Monday afternoon.